San Francisco Business Times

Peninsula biotech coughs up 40 percent of its value on failed clinical trial
San Francisco Business Times
CEO Steve Basta said in a statement that the company is moving forward with serlopitant as a potential solution for psoriasis and prurigo nodularis, or itchy skin nodules that appear on the legs and arms. The mid-stage psoriasis trial is expected to
Menlo Therapeutics (MNLO) Sets New 12-Month Low at $6.02Fairfield Current

all 6 news articles »